Literature DB >> 33580827

Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing.

Shihan Zhang1, Weiling Zhang2, Mei Jin1, Qing Sun3, Zhaoxia Zhang4, Hong Qin5, Yan Su1, Tian Zhi2, Yao Xie3, Yang Xu Gao3, Xiaolun Zhang4, Long Li4, Rong Liu6, Weihong Zhao7, Huanmin Wang8, Dongsheng Huang9, Xiaoli Ma10.   

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, with 37% of patients diagnosed during infancy. This study is aimed at evaluating the survival outcome in infants diagnosed with neuroblastoma. This was a retrospective cohort study including patients under the age of 12 months with neuroblastoma from four tertiary referral centers in Beijing, China (Beijing Children's Hospital, Beijing Tongren Hospital, Peking University First Hospital, and Capital Institute of Pediatrics). Two hundred and forty-seven infants with neuroblastoma were included (male = 132 and female = 115). 91.1% (n = 225) patients were classified as having low-risk or intermediate-risk disease and 8.9% (n = 22) as having high-risk disease. The most common metastatic site is distant lymph node (n=89, 36.0%), followed by liver (n=57, 23.1%), bone (n=42, 17.0%), bone marrow (n=37, 15.0%), soft tissue (n=25, 10%), and central nervous system (n=4, 1.6%). MYCN amplification was present in 9.9% of tumor samples, chromosome 1p or 11q aberration in 14%. Treatment involved surgery alone in 9.7% of patients (n=24, all with low-risk disease), surgery followed by adjuvant chemotherapy in 50.2% (n=124), neoadjuvant chemotherapy followed by surgery in 40.1% (n=97), and chemotherapy alone in 0.8% (n=2). 4.9% (n=12) patients died, and the major cause of death is disease progression. Three-year event-free and overall survival were 91.6%±2.1% and 97.4%±1.1%, respectively, in patients with low- or intermediate-risk disease, and 58.7%±11.5% and 63.6%±11.2%, respectively, in those with high-risk disease.Conclusions: Infants with neuroblastoma achieve a reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. Such information will facilitate counseling, therapeutic decision-making, and development of adapted standard-of-care guidelines for future patients in the country. What is Known: • NB is a disease of infancy; 37% of patients are diagnosed as infants. • Most children younger than 12 months of age have a good prognosis even in the presence of metastatic disease. What is New: • Infants with neuroblastoma achieve reasonable clinical outcome when treated with surgery with or without chemotherapy using a risk-stratified approach in China. • CNS metastasis in infants with neuroblastoma is very rare at diagnosis and had a worse prognosis than those without metastasis.

Entities:  

Keywords:  Infant; Multicenter; Neuroblastoma; Outcome

Year:  2021        PMID: 33580827     DOI: 10.1007/s00431-021-03989-1

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  1 in total

1.  Heterogeneity of the MYCN oncogene in neuroblastoma.

Authors:  Jessica Theissen; Marc Boensch; Ruediger Spitz; David Betts; Sabine Stegmaier; Holger Christiansen; Felix Niggli; Freimut Schilling; Manfred Schwab; Thorsten Simon; Frank Westermann; Frank Berthold; Barbara Hero
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

  1 in total
  2 in total

1.  [Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].

Authors:  Wei-Ling Liang; Xiao-Fan Ye; Gong Zhong; Jian-Jun Chen; Kang-Lin Dai; Ka Leung Daniel Cheuk; Shu Mo; Bo-Shen Wang; Chun-Yu Li; Xuan-Zhu Jiang; Zhi-Yuan Xu; Li Zhou; Irene Chan; Jian-Liang Chen; Patrick Chu; Pui Wah Pamela Lee; Chi Fung Godfrey Chan
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15

2.  Effects of Surgery Combined with Different Chemotherapy on Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinase-1 in Children with Neuroblastoma.

Authors:  Zilong Qi; Xinning Wang; Liang Yin; Kun Ma; Lei Chen; Jinmin Li
Journal:  J Oncol       Date:  2022-07-05       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.